Although AIM2 inflammasome activation has been shown to be sufficient to promote atherosclerosis in Jak2 CH (15), our findings suggest that other pathways may also contribute to ASXL1-mediated CVD risk (Figure 3 and 4). The gene discussed is ASXL1; the disease is atherosclerosis.